Better Health for All

The company's core product, ProSense cryoablation, provides exceptional health benefits by offering a minimally invasive alternative to surgery for tumors. The ICE3 trial for early-stage breast cancer demonstrated a 96.3% recurrence-free rate at 5 years, with 100% patient and physician satisfaction and no serious device-related adverse events.

For kidney tumors, the ICESECRET study reported an 83.8% success rate in tumor ablation. However, the ICESECRET study also reported 4 serious adverse events, including one severe, among 114 patients, resulting in an adverse event rate of approximately 35,088 per million patients. The ProSense system is reimbursed under a CPT III code covering $3,800 in facility costs, but the product's cost or specific discount programs are not provided. The target market for breast cancer treatment is women aged 70 and over, estimated at 46,000 patients annually in the US, but there is no evidence of specific programs to reach low-income or marginalized populations. Clinical trials like ICE3 and ICESECRET were conducted at multiple medical centers with structured follow-up schedules and published in peer-reviewed journals, indicating strong ethical conduct.

Fair Money & Economic Opportunity

IceCure Medical Ltd. is a medical device company that develops and markets cryoablation technology.

The 'Fair Money & Economic Opportunity' value is designed to assess financial institutions that lend, insure, move, or store money. The provided articles focus on the company's medical products, financial performance, and corporate financing activities (share offerings, bridge loans). There is no evidence that the company offers lending, insurance, or other financial services to consumers or businesses. Therefore, all KPIs under this value are not applicable, as the company's core business lies outside financial services, and it does not offer financial products or services to consumers.

Fair Pay & Worker Respect

As of December 31, 2023, employees are not represented by labor unions.

The company had 71 full-time and 6 part-time employees as of December 31, 2023, and 64 full-time and two part-time employees as of December 31, 2024. Ten employees were called up as Israeli military reservists in October 2023, and nine as of March 24, 2025, with almost all having since returned to employment. The company has a Compensation Committee and a Compensation Policy, which addresses the relationship between executive compensation and the average median compensation of other employees. The company also has non-competition agreements with all employees, governed by Israeli law, and may be required to pay monetary remuneration to Israeli employees for their inventions.

Fair Trade & Ethical Sourcing

No specific, concrete data points regarding fair trade and ethical sourcing practices were found in the provided articles. Information on fair-trade certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend is not available.

The articles primarily focus on financial performance and general internal ethical conduct, explicitly stating a lack of relevant data for these metrics.

Honest & Fair Business

The company has a formal whistleblower protection policy that requires reporting violations to the board or audit committee and details a process for investigating breaches.

However, there is no evidence of a dedicated hotline, independent investigation processes, or any metrics regarding its effectiveness, training, or uptake. The company's code of ethics outlines anti-corruption and anti-bribery policies, but specific details on their strength, enforcement, or third-party due diligence are not provided, nor is there mention of training frequency or effectiveness metrics.

Kind to Animals

The company engages in animal testing, as explicitly stated in one article.

Another article mentions "pre-clinical studies" and "animal testing results" in the context of FDA approval processes, further confirming its involvement. However, no explicit animal testing policy is stated in the provided information.

No War, No Weapons

IceCure Medical is a medical device company focused on cryoablation systems for tumor treatment. The company's products are for medical use and have no apparent connection to the arms industry, military contracts, or conflict facilitation.

, There is no evidence of revenue from arms contracts, dual-use technology for military purposes, or sales to embargoed regimes. , Therefore, based on the available information, there is insufficient evidence to assess the company's alignment with the 'No War, No Weapons' value. ,

Respect for Cultures & Communities

No specific, concrete evidence was found in the provided articles regarding ICCM.US's performance on any of the KPIs related to 'Respect for Cultures & Communities'.

The articles primarily cover financial results, regulatory updates, and a general code of ethics, none of which contain data points for formal partnerships, community reinvestment, cultural incidents, impact protocols, local employment, grievance mechanisms, or other community-related metrics.